CIR Share Price

Open 0.30 Change Price %
High 0.31 1 Day 0.00 0.00
Low 0.30 1 Week 0.00 0.00
Close 0.31 1 Month 0.00 0.00
Volume 70000 1 Year 0.00 0.00
52 Week High 33.50
52 Week Low 30.88
CIR Important Levels
Resistance 2 0.32
Resistance 1 0.32
Pivot 0.31
Support 1 0.30
Support 2 0.30
ASX Australia Most Active Stocks
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
AGO 0.01 0.00%
AGO 0.01 0.00%
AGO 0.01 0.00%
TLS 4.36 0.93%
TLS 4.36 0.93%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
GCR 0.02 100.00%
GCR 0.02 100.00%
GBG 0.02 100.00%
GBG 0.02 100.00%
GBG 0.02 100.00%
PMQ 0.03 50.00%
BNV 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
DAU 0.02 -33.33%
More..

Circadian Technologies Ltd (ASX: CIR)

CIR Technical Analysis 4
As on 11th Dec 2015 CIR Share Price closed @ 0.31 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.19 & Buy for SHORT-TERM with Stoploss of 0.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
CIR Target for June
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CIR Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.circadian.com.au
CIR Address
CIR
650 Chapel Street
Suite 0403
South Yarra, VIC 3141
Australia
Phone: 61 3 9826 0399
Fax: 61 3 9824 0083
CIR Latest News
Active Runner in Focus: Opthea Ltd (OPT.AX)   Clayton News   - 26th Jun 17
Opthea Completes A$45 Million Capital Raising   Marketwired (press release)   - 28th Apr 17
Why the Opthea Ltd share price rocketed 38% today   Motley Fool Australia   - 05th Apr 17
BRIEF-Opthea launches A$45 mln financing for clinical development   Reuters   - 03rd Apr 17
Opthea Reports Positive Phase 1/2A Clinical Results for OPT-302 in wet AMD   Marketwired (press release)   - 03rd Apr 17
Opthea receives positive feedback for macular degeneration therapy   Proactive Investors Australia   - 21st Mar 17
Opthea Completes FDA Meeting to Inform OPT-302 wet AMD Clinical Program   Marketwired (press release)   - 09th Mar 17
Is Opthea Ltd a buy on today's results?   Motley Fool Australia   - 26th Jul 16
Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective   Marketwired (press release)   - 21st Apr 16
Opthea Signs Cell Line Development Commercial License Agreement with Selexis ...   PR Newswire (press release)   - 14th Jan 14
Interactive Technical Analysis Chart Circadian Technologies Ltd ( CIR ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Circadian Technologies Ltd
CIR Business Profile
Circadian Technologies Limited develops and commercializes therapies for cancer and eye diseases in Australia. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and R3 targets. The company’s product pipeline includes anti-VEGFR-3 antibody that is in Phase I clinical trials for the treatment of solid tumours; VGX-100, a human antibody against VEGF-C, as a treatment for lymphedema resulting from breast cancer treatment and solid tumours; and VGX-300, a soluble form of VEGFR-3 for ‘back of the eye’ disease. It also develops diagnostic test products for cancers of unknown primaries; and blood based diagnostic tests for VEGF-C and VEGF-D as predictive and prognostic tests in lymphangioleiomyomatosis and cancer patients. The company is based in South Yarra, Australia.